SeqUential GeMcitabine and MITomycin Treatment for Favorable High-Risk Upper Urinary Tract Urothelial Carcinoma

NCT06822010 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

28

Enrollment

OTHER

Sponsor class

Conditions

Urinary Bladder Cancer
Upper Tract Urothelial Cancer
Urothelial Cancer

Interventions

DRUG: Sequential Gemcitabine and Jelmyto Treatment (Gem/Jel)

Sponsor

Rutgers, The State University of New Jersey